lemingshi@fudan.edu.cn

摘要

Andres Ruiz-Linares has been working for a number of years on the genetics of populations from Latin America, including evolutionary analyses as well as gene mapping studies. His work has sought to exploit the advantages of the region for the study of human and population genetic questions of broad scientific relevance. Of special interest to this proposal the history of extensive intercontinental admixture in the region implies that the population of Latin America represents a highly informative “natural experiment” in which to analyse the role of genetic factors in phenotypic diversity, particularly for traits differentiated between Africans, Europeans and Native Americans.

Dr. Shi received his Ph.D. in computational chemistry and chemometrics from the Chinese Academy of Sciences in Beijing, M.Sc. in chemometrics from the University of Science and Technology of China in Hefei, and B.Sc. in analytical chemistry from Hunan University in Changsha, China. Dr. Shi conducted postdoctoral training at Case Western Reserve University and the NIH/NCI. Dr. Shi was a senior research scientist at Wyeth (now Pfizer) and BASF before co-founding Chipscreen in 2001. Dr. Shi is a guest faculty at the US FDA and an adjunct professor of medicine at the University of Arkansas for Medical Sciences.

Dr. Leming Shi is a distinguished professor at the School of Life Sciences of Fudan University in Shanghai, China where he established and directs the Center for Pharmacogenomics and Fudan-Zhangjiang Center for Clinical Genomics.

As a principal investigator at the US Food and Drug Administration (FDA) from 2003 to 2012, Dr. Shi conceived and led the MicroArray and Sequencing Quality Control (MAQC/SEQC) project aimed at realizing precision medicine by standardizing genomics and bioinformatics (www.nature.com/nbt/focus/maqc/, www.nature.com/focus/maqc2/, and www.nature.com/nbt/collections/seqc/).

Dr. Shi was a co-founder of Chipscreen Biosciences Ltd. in Shenzhen, China where he co-developed a chemogenomics-based drug discovery platform leading to several novel small-molecule drug candidates with promising efficacy and safety profiles in anticancer and antidiabetic clinical trials, with one novel compound approved in 2014 by China FDA for treating T-cell lymphoma.

Dr. Shi’s research focuses on pharmacogenomics, bioinformatics, and cheminformatics aiming to realize precision medicine by developing biomarkers for early cancer diagnosis and targeted therapy.

Dr. Shi is a co-inventor on nine issued patents about novel therapeutic molecules and has published over 200 peer-reviewed papers (11 of them appeared in Nature Biotechnology) with over 8,000 citation by SCI journals.

1. Wang J#, Yu Y#, Shen H, Qing T, Zheng Y, Li Q, Mo X, Wang S, Li N, Chai R, Xu B, Liu M, Brindley PJ, McManus DP, Feng Z, Shi L, Hu W. Dynamic transcriptomes identify biogenic amines and insect-like hormonal regulation for mediating reproduction in Schistosoma japonicum. Nature Communications, 8:14693 (2017).

2. Zhu J, Chen G, Zhu S, Li S, Wen Z, Bin Li, Zheng Y*, Shi L*. Identification of Tissue-Specific Protein-Coding and Noncoding Transcripts across 14 Human Tissues Using RNA-seq. Scientific Reports, 6:28400 (2016)

3. Chen G, Schell JP, Benitez JA, Petropoulos S, Yilmaz M, Reinius B, Alekseenko Z, Shi L, Hedlund E, Lanner F, Sandberg R, Deng Q*. Single-cell analyses of X Chromosome inactivation dynamics and pluripotency during differentiation. Genome Research, 26(10), 1342-1354 (2016)

4. MetaSUB International Consortium (Shi L was listed as a co-PI). The Metagenomics and Metadesign of the Subways and Urban Biomes (MetaSUB) International Consortium inaugural meeting report. Microbiome, 4(1), 24 (2016)

5. Zhang W#, Yu Y#, Hertwig F#, …, Shi L*, Peng Z*, Fischer M*. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biology, 16(1), 133 (2015)